Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Inclusion Criteria

• Part I: Histologically confirmed advanced/metastatic solid tumor (except prostate cancer and squamous non-small cell lung cancer [NSCLC])
• Part II: Histologically confirmed advanced/metastatic platinum-resistant ovarian carcinoma (aPROC), head and neck squamous cell carcinoma (HNSCC), or non-squamous NSCLC previously treated with anti-PD-L1/PD-1 inhibitor alone or in combination (e.g. atezolizumab, nivolumab, pembrolizumab, durvalumab, avelumab)
• Checkpoint inhibitor (CPI)- experienced patients must have experienced documented disease progression on or after PD-L1/PD-1 inhibitor therapy
• In CPI-experienced patients, the PD-L1/PD-1 inhibitor must have been part of the most recent systemic anticancer therapy administered prior to study enrollment
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Life expectancy >/= 16 weeks
• Adequate hematologic, renal, hepatic, and cardiovascular function
• Measurable disease per Response Evaluation Criteria in Solid Tumors, v 1.1 (RECIST v1.1)
• Tumors must be acceptable for biopsy. Participants in Part II may be enrolled without a biopsy if the collection is not clinically feasible.
• Agreement to use adequate contraceptive measures among men or among women of childbearing potential

Exclusion Criteria

• Prostate cancer or squamous NSCLC
• Recent systemic anti-cancer treatment
• Prior treatment with anti-programmed death (PD) 1 or anti-programmed death ligand (PD-L) 1 therapeutic antibody, vanucizumab, or compounds targeting cluster of differentiation (CD) 40 less than 4 weeks or 5xt1/2 (whichever is shorter) prior to enrollment
• Part II: Treatment targeting vascular endothelial growth factor (VEGF) or receptor within 12 months prior to enrollment
• Systemic immunosuppressive medication within 2 weeks prior to day 1 of cycle 1
• Chronic daily treatment with non-steroidal anti-inflammatory drugs
• Unacceptable/unresolved toxicity from prior anti-cancer therapy
• Patients who have had a surgical procedure or significant traumatic injury within 28 days prior to initiation of study treatment, or a core biopsy or other minor surgical procedure within 7 days prior to initiation of study treatment
• Bisphosphonate therapy for symptomatic hypercalcemia
• Significant vascular disease
• History of hypertensive crisis or hypertensive encephalopathy
• Current or recent use of aspirin (>325 mg/day) or clopidogrel (>75 mg/day)
• History of vein thrombosis/thromboembolism, or use of anticoagulants within 7 days prior to study drug
• Primary tumor in place in participants with colorectal cancer, or evidence of bowel involvement (metastasis, direct tumor invasion) in participants with other non-gastrointestinal cancer
• Significant cardiovascular or cerebrovascular disease within 6 months prior to D1 of C1
• History of fistula, bowel obstruction, perforation, or abscess
• Prior radiotherapy to pelvis or abdomen, recto-sigmoid involvement, or bowel involvement among participants with aPROC
• Severe non-healing wound, active ulcer or untreated bone fracture
• Pregnant or lactating women
• History of autoimmune disease
• Human immunodeficiency virus (HIV) or hepatitis B or C
• Severe infection or receipt of a live/attenuated vaccine within 4 weeks prior to D1 of C1
• Other significant malignancies within 3 years prior to D1 of C1
• Allergy/hypersensitivity to study drug
• Prior allogeneic bone marrow or solid organ transplant
• Other conditions/findings that may contraindicate use of study drug
• Major surgery within 4 weeks prior to study drug
• Known clinically significant liver disease
• History of hemoptysis or bleeding diathesis, or known coagulopathies
• Known symptomatic or untreated central nervous system (CNS) malignancy